CL2017001592A1 - Complejos radiofarmacéuticos. - Google Patents
Complejos radiofarmacéuticos.Info
- Publication number
- CL2017001592A1 CL2017001592A1 CL2017001592A CL2017001592A CL2017001592A1 CL 2017001592 A1 CL2017001592 A1 CL 2017001592A1 CL 2017001592 A CL2017001592 A CL 2017001592A CL 2017001592 A CL2017001592 A CL 2017001592A CL 2017001592 A1 CL2017001592 A1 CL 2017001592A1
- Authority
- CL
- Chile
- Prior art keywords
- fabric
- torio
- complainant
- coupling
- complex
- Prior art date
Links
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- 239000004744 fabric Substances 0.000 abstract 4
- 230000008878 coupling Effects 0.000 abstract 3
- 238000010168 coupling process Methods 0.000 abstract 3
- 238000005859 coupling reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- ZSLUVFAKFWKJRC-UHFFFAOYSA-N thorium Chemical compound [Th] ZSLUVFAKFWKJRC-UHFFFAOYSA-N 0.000 abstract 3
- -1 CARBOXYL Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002914 neoplasic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>LA INVENCIÓN PROVEE UN MÉTODO PARA LA FORMACIÓN DE UN COMPLEJO DE TORIO DIRIGIDO A TEJIDO, EN DONDE DICHO MÉTODO COMPRENDE; A) FORMAR UN QUELANTE OCTADENTADO QUE COMPRENDE CUATRO PORCIONES HIDROXIPIRIDINONA (HOPO) SUSTITUIDAS EN LA POSICIÓN N CON UN GRUPO C1-C3ALQUILO, Y UNA PORCIÓN DE ACOPLAMIENTO QUE TERMINA EN UN GRUPO ÁCIDO CARBOXÍLICO; B)ACOPLAR DICHO QUELANTE OCTADENTADO A POR LO MENOS UN PÉPTIDO O PROTEÍNA DE DIRECCIONAMIENTO A TEJIDO QUE COMPRENDE POR LO MENOS UNA PORCIÓN AMINA POR MEDIO DE POR LO MENOS UN REACTIVO DE ACOPLAMIENTO DE AMIDA PARA GENERAR ASÍ UN QUELANTE DE DIRECCIONAMIENTO A TEJIDO; Y C) PONER EN CONTACTO DICHO QUELANTE DE DIRECCIONAMIENTO A TEJIDO CON UNA SOLUCIÓN ACUOSA QUE COMPRENDE UN ION DE POR LO MENOS UN ISÓTOPO DE TORIO EMISOR ALFA. UN MÉTODO DE TRATAMIENTO DE UNA ENFERMEDAD NEOPLÁSICA O HIPERPLÁSICA QUE COMPRENDE LA ADMINISTRACIÓN DE DICHO COMPLEJO DE TORIO DIRIGIDO A TEJIDO, ASÍ COMO TAMBIÉN SE PROVEEN EL COMPLEJO Y FORMULACIONES FARMACÉUTICAS CORRESPONDIENTES.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422512 | 2014-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001592A1 true CL2017001592A1 (es) | 2018-03-16 |
Family
ID=54884033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001592A CL2017001592A1 (es) | 2014-12-17 | 2017-06-16 | Complejos radiofarmacéuticos. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20170340759A1 (es) |
| EP (1) | EP3233137A1 (es) |
| JP (2) | JP6821569B2 (es) |
| KR (1) | KR20170094223A (es) |
| CN (1) | CN107278155B (es) |
| AR (1) | AR103063A1 (es) |
| AU (2) | AU2015367722A1 (es) |
| BR (1) | BR112017012841A2 (es) |
| CA (1) | CA2970841A1 (es) |
| CL (1) | CL2017001592A1 (es) |
| CO (1) | CO2017005975A2 (es) |
| CR (1) | CR20170256A (es) |
| CU (1) | CU24493B1 (es) |
| DO (1) | DOP2017000143A (es) |
| EA (1) | EA201791350A9 (es) |
| EC (1) | ECSP17038089A (es) |
| IL (1) | IL252244B (es) |
| JO (1) | JOP20150319B1 (es) |
| MA (1) | MA41176A (es) |
| MX (1) | MX384088B (es) |
| MY (1) | MY194190A (es) |
| NI (1) | NI201700076A (es) |
| PE (2) | PE20171181A1 (es) |
| PH (1) | PH12017501125A1 (es) |
| SG (1) | SG11201704917XA (es) |
| TN (1) | TN2017000255A1 (es) |
| TW (1) | TWI654179B (es) |
| UA (1) | UA125369C2 (es) |
| UY (1) | UY36453A (es) |
| WO (1) | WO2016096843A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190168A1 (es) * | 2016-03-24 | 2019-02-01 | Bayer Pharma AG | Complejos radiofarmaceuticos |
| WO2017211809A1 (en) * | 2016-06-10 | 2017-12-14 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| EP3585436A1 (en) * | 2017-02-24 | 2020-01-01 | Bayer AS | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| EP3600452B1 (en) * | 2017-03-30 | 2024-09-04 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| EP3843743A1 (en) | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| CA3130809A1 (en) | 2019-02-22 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| EP4003959A1 (en) | 2019-07-25 | 2022-06-01 | Bayer AS | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| AU2024339683A1 (en) | 2023-09-13 | 2026-03-26 | Toray Industries, Inc. | Pharmaceutical composition for treating, preventing and/or diagnosing cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Withdrawn
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 MX MX2017008093A patent/MX384088B/es unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en not_active Ceased
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es not_active Application Discontinuation
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001592A1 (es) | Complejos radiofarmacéuticos. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| CL2018003550A1 (es) | Complejos radio-farmacéuticos. | |
| CL2017003307A1 (es) | Sistema de administración dirigida de principio activo celular | |
| BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
| CL2014001930A1 (es) | Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2). | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| GT201700184A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| CO2017007316A2 (es) | Formulación farmacéutica | |
| MX366499B (es) | Composicion farmaceutica liquida. | |
| MX2017000676A (es) | Oritavancina de alta pureza y metodo para producir la misma. | |
| BR112015030135A2 (pt) | ésteres de ácidos oligo-hidróxi carboxílicos e seu uso | |
| MX2018002514A (es) | Citotoxinas modificadas y su uso terapeutico. | |
| BR112017004595A2 (pt) | composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio | |
| CL2018002695A1 (es) | Complejos radiofarmacéuticos | |
| BR112015030129A2 (pt) | ésteres sulfatados de ácido oligohidróxi carboxílico e seu uso | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| BR112019023074A2 (pt) | composição contendo ciclodextrina e bussulfano | |
| EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| UA107907C2 (en) | Composition in a gel for the treatment of acne | |
| EA201600142A1 (ru) | Новые комплексы агомелатина и сульфокислот, способ их получения и фармацевтические композиции, которые их содержат |